Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 20, 2025

Language: Английский

---

Updates on the Treatment of Richter’s Syndrome, Including Novel Combination Approaches

Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 943 - 943

Published: March 11, 2025

Richter’s syndrome (RS) or transformation of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma (e.g., diffuse large B cell lymphoma, DLBCL) is distinct disease that portends an overall poor prognosis and remains challenge for clinicians to identify treat effectively. This review the current literature focuses on pathology, diagnosis, management syndrome. Clonally related RS has been found have worse than unrelated genomic profile DLBCL-RS differs from de novo DLBCL. The standard care therapy historically chemoimmunotherapy; consolidative stem transplants role in improving durability response. Given generally response rates chemotherapy, there recent investigations combination treatments with immune checkpoint inhibitors small molecule targeted therapies, which had mixed results. Additional studies are evaluating use bispecific antibodies, chimeric antigen receptor T therapy, antibody drug conjugates. difficult manage; however, advancements understanding underlying pathology continued new therapies demonstrate promise future.

Language: Английский

---

Richter Transformation in the Canadian Landscape: Clinical Perspectives and Emerging Trends

Canadian Hematology Today, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Over the past decade, treatment landscape for chronic lymphocytic leukemia (CLL) and its lymphoma counterpart, small (SLL), has evolved significantly. The shift from chemoimmunotherapy (CIT) to increased use of targeted agents, such as Bruton’s tyrosine kinase inhibitors (BTKi) B-cell 2 (BCL2i), led marked improvements in patient outcomes. Despite these advancements, some patients still experience disease transformation a more aggressive histology known Richter Transformation (RT), clinical outcomes with this remain dismal, median overall survival (OS) typically shorter than one year. Therefore, RT represents significant unmet need CLL/SLL. This review describes recent advances understanding management within Canadian landscape, focusing on diffuse large (DLBCL).

Language: Английский

---

Overcoming the unmet need of Richter transformation: the use of pirtobrutinib

The Lancet Haematology, Journal Year: 2024, Volume and Issue: 11(9), P. e636 - e637

Published: Sept. 1, 2024

Language: Английский

---